

AD_____

GRANT NO: DAMD17-94-J-4397


TITLE: The Role of HAP Kinases in Breast Cancer

PRINCIPAL INVESTIGATOR: John M. Kyriakis, Ph.D.

CONTRACTING ORGANIZATION: Massachusetts General Hospital
Boston, MA 02114

REPORT DATE: 8/29/95

TYPE OF REPORT: Annual



PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

19951018 029

DTIC QUALITY INSPECTED 5

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 8/29/95	3. REPORT TYPE AND DATES COVERED Annual - 19 Aug 94 - 28 Aug 95	
4. TITLE AND SUBTITLE The Role of HAP Kinases in Breast Cancer			5. FUNDING NUMBERS DAMD17-94-J-4397	
6. AUTHOR(S) John M. Kyriakis, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Massachusetts General Hospital Boston, MA 02114			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) We have characterized a mammalian signal transduction pathway which is activated by TNF and IL-1, two cytokines which can inhibit the growth of some mammary tumor lines. This pathway uses a subfamily of the ERKs, the stress-activated protein kinases (SAPKs). SAPKs are the dominant kinases responsible for activation of the transactivation function of the transcription factor c-Jun. As such, the SAPKs relay TNF signals to the cell nucleus, thereby regulating gene expression in response to TNF. During the past year, we have identified SAPK/ERK kinase-1 as a kinase which activates the SAPKs in situ, and MAPK/ERK kinase-kinase (MEKK1) as an in situ SAPK/ERK kinase (SEK1) activator. insofar as SEK is a novel member of the MEK family and MEKK 1 is a homolog of yeast STE11, the SAPK pathway is homologous to yeast MEKK-MEK-ERK signaling modules. These modules are themselves regulated by members of the STE20 family of protien kinases. Consistent with this, we observe that the SAPK pathway can be activated by the mammalian STE20 homolog, GC kinase. GC kinase is also activated in situ by TNF. Thus, TNF activates a pathway consisting of GC kinase--MEKK-SEK1-SAPK-c-Jun. We propose that this pathway may mediate inhibition of mammary cell growth in response to TNF.				
14. SUBJECT TERMS protein kinase, TNF, ERK, SAP kinase, signal transduction, c-Jun kinase.			15. NUMBER OF PAGES 13	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet optical scanning requirements.

Block 1. Agency Use Only (Leave blank).

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in.... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement.

Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

Block 13. Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code (*NTIS only*).

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the US Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

ML In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

ML In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

ML In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

ML In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Accession For	
NTIS GRA&I	<input checked="checked" type="checkbox"/>
DTIC TAB	<input type="checkbox"/>
Unannounced	<input type="checkbox"/>
Justification	
By _____	
Distribution/_____	
Availability Codes	
Dist.	Avail and/or Special
A-1	

ML 8/21/95
PI - Signature Date

TABLE OF CONTENTS

ITEM	PAGE
Front Cover	1
SF298 Report Documentation Page	2
Foreword	3
Table of Contents	4
Introduction	5
Body	5
Conclusions	11
References	12

INTRODUCTION

We have elucidated a second mammalian signaling pathway which responds primarily to stress and the inflammatory/pro-apoptotic cytokines TNF- α and IL-1. This finding has implications for the understanding of the inflammatory response and controlled cell death. This pathway, uses a member of the extracellular signal-regulated protein kinase family, the p54 heat-activated protein kinases (HAPKs, now renamed SAPKs for stress-activated protein kinases) as a multifunctional effector which, among other things, phosphorylates and activates transcription factors. Specifically, our past findings indicate that the SAPKs are the dominant c-Jun kinases, as well as ATF-2 kinases, activated by TNF- α . Thus, one purpose of the SAPKs is the relaying of inflammatory/stress/apoptotic signals to the nucleus. As such, the SAPKs have an important role in the regulation of gene expression in response to cellular/physiologic stress and apoptotic agonists. The implication of TNF- α as a SAPK agonist indicates that this important breast cell growth inhibitor likely uses the SAPKs to influence gene expression in breast cells.

The SAPKs are part of a multi-tiered protein kinase cascade which is strikingly similar to signaling modules in yeast. In these pathways, members of the *STE20* family of protein kinases phosphorylate and activate a cassette of signaling kinases consisting of a MEK-kinase (MEKK) which activates a MAPK/ERK kinase (MEK) which, in turn, activates an ERK. ERKs serve to distribute the signal to the downstream components brought to bear in response to the particular extracellular stimulus (1). Consistent with the homology between yeast and mammalian signaling mechanisms, we have now identified components in the SAPK pathway which lie upstream of the SAPKs and identified them as members of the MEK, MEKK and *STE20* kinase families.

As outlined in the original proposal, it is the aim of this project to characterize the regulation, and cellular role of the SAPKs. These studies have been divided into four major areas.

- 1) *What are the cellular agonists which activate the SAPKs?*
- 2) *What are the immediate upstream activators of the SAPKs?* A primary goal of this project will be the identification of protein kinase cascades capable of activating the SAPKs *in situ*.
- 3) *Do the SAPKs activate MAPKAP-kinase-2?* The true *in vivo* substrates of the SAPKs, aside from c-Jun, are not known. These studies will identify protein substrates of the SAPKs whose physiologic function is changed by SAPK phosphorylation.
- 4) *Do the SAPKs have a role in mammary tissue proliferation?*

BODY: 8/94-8/85

During the past year, the investigations in this laboratory have focussed primarily on the elucidation of the protein kinase components upstream of the SAPKs and the downstream targets of the SAPKs. The following conclusions were drawn using the techniques described:

- 1) *MAPKAP kinase-2 (MAPKAP-K2) is not a SAPK substrate.* Using purified proteins (MAPKAP-K2 was kindly provided by Prof. Philip Cohen, University of Dundee) we have demonstrated that SAPK cannot phosphorylate and activate MAPKAP-K2. Fig. 1 illustrates these results.

Effect of HepG2 cell SAPKs on MAPKAP kinase-2




Fig. 1. SAPK does not reactivate phosphatase-2A-inactivated MAPKAP-K2. SAPK was immunoprecipitated from HepG2 cells treated with the ligands indicated and incubated with purified MAPKAP-K2 which had been inactivated with phosphatase-2A as indicated. After centrifugation to remove the SAPK beads, MAPKAP-K2 was assayed as described.

2) *Identification of SAPK/ERK Kinase-1 (SEK1) as an Upstream Activator of the SAPKs.* Using recombinant SAPK as a substrate, the PI-s laboratory has identified a novel member of the mitogen-activated protein kinase/extracellular signal regulated kinase-kinase (MEK) family, SEK1, as an upstream activator of the SAPKs. SEK1 was cloned in the laboratory of Dr. Leonard Zon, with whom we collaborated in these studies. SEK1 is completely specific for the SAPKs, being unable to activate the MAPKs *in situ* or *in vitro*. SEK1 activity is activated preferentially by the same stress stimuli which activate the SAPKs *in situ*. These results further illustrate the segregation between the mitogen-activated Ras/MAPK pathway and the SAPK stress-regulated pathway (2,3); and support the contention that mammals, like yeast possess multiple, homologous signaling pathways which respond to distinct types of extracellular stimuli. Fig. 2 illustrates activation of the SAPKs *in situ* by purified SEK1 (1-3).




Fig. 1. Activation of SAPKs by SEK1. SEK1 was purified from transfected cells and assayed for activation of purified recombinant SAPKs p54 α I and p54 β I. Assays were performed as in Sánchez, *et al.* (1994).

These studies were published in: Sánchez, I *et al.* (1994) *Nature*. **372**, 794-798.

3) *Identification of MEK-kinase-1 (MEKK1) as an Upstream Activator of SEK1 and the SAPK Pathway.* MEKK1 is a mammalian homolog of the yeast MEK activators Ste11 and Byr2 (4). Originally, MEKK1 was thought to act as a mitogen-activated, Raf-1-independent mechanism of MEK activation (4). Using an inducible MEKK1 construct, in collaboration with Dr. Dennis Templeton, we have demonstrated that MEKK1 preferentially activates the SAPK pathway, via activation of SEK1 (5). These studies, further delineate the segregation of the SAPK and MAPK pathways and strikingly illustrate the homology between yeast and mammalian signaling mechanisms. Fig. 3 illustrates *in situ* activation of SAPK upon coexpression with MEKK1.




Fig. 3. Coexpression with MEKK1 activates SAPK. This activation is blocked by triple transfection with a nonactivatable SEK1 mutant.

Fig. 4 illustrates the ability of purified MEKK1, *in vitro* to activate the SAPK activating activity of SEK1.




Fig. 4. MEKK1, SEK1 and SAPK-p54 α l were expressed as GST fusion proteins in *E. coli* and purified by glutathione affinity chromatography. Purified MEKK1 was then tested for its ability to activate SEK1 SAPK activating activity in this coupled assay.

These studies were published in: Yan, M. *et al.* (1994) *Nature*. **372**, 798-800.

4) *Identification of GC Kinase, a Mammalian STE20 Homolog, as an Activator of the SAPK Pathway.* In yeast, the MEKK \rightarrow MEK \rightarrow ERK core kinase modules are thought themselves regulated by members of the STE20 family of protein kinases (1). GC kinase is a ubiquitously expressed mammalian STE20 homolog which, in lymphoid follicles is thought to participate in B cell maturation (6). GC kinase was cloned in Dr. John Kehrl's laboratory and he has generously provided us with the clone. We have now shown that GC kinase is a potent, specific *in situ* activator of the SAPK pathway, and overexpression of the GC kinase activates both SEK1 and the SAPKs. Figs. 5 and 6 illustrate activation of SAPK and SEK1, respectively upon coexpression with GC kinase. In Fig. 7, it is clear that GC kinase does not activate two other ERK pathways, the p42/p44 MAPK or p38/mpk2 pathway (7).

transfections:




Fig. 5. Activation *in situ* of SAPK by GC kinase. 293 cells were transfected with HA-tagged SAPK and GC kinase or the cognate empty plasmid. SAPK was immunoprecipitated and assayed.




Fig. 6. Activation *in situ* of SEK1 upon coexpression with GC kinase. 293 cells were transfected with GST-tagged SEK1 and either GC kinase or cognate empty plasmid. SEK1 was purified by glutathione agarose affinity chromatography and assayed for activation of SAPK.




Fig. 7. Coexpression with GC kinase in COS cells activates the SAPK pathway (part *a*) but does not activate the p42/p44 MAPK pathway (part *b*, ERK1) or the p38 pathway (part *c*) in spite of the fact that these two pathways are intact and can be activated, respectively by oncogenic Raf-1 (BXB-Raf) or by hyperosmotic shock (NaCl).

We have also obtained preliminary data indicating that GC kinase is in part regulated by an inhibitor which is present in limiting amounts in the cell and which interacts with the C-terminal noncatalytic domain of GC kinase. In support of this we observe that overexpression of the GC kinase C-terminus activates the SAPK pathway likely by competing away this inhibitor.

These studies have been submitted for publication as: Pombo, C.M., *et al.* *Nature*. submitted.

The work outlined above, as well as related projects in other areas have resulted in the following publications during the period 8/19/94-8/28/95. This level of productivity would not have been possible without the Army funding. No meeting abstracts were published or submitted.

Kyriakis, J.M. and Avruch, J. (1995) S6 kinases and MAP kinases: Sequential intermediates in insulin/mitogen-activated protein kinase cascades. In: *Protein Kinases: Frontiers in Molecular Biology*, J.R. Woodgett, ed., Oxford University Press: Oxford.

Avruch, J., Zhang, X.-f. and Kyriakis, J.M. (1994) Raf meets Ras: closing a frontier in signal transduction. *Trends Biochem. Sci.* 19: 279-283.

Pombo, C.M., Bonventre, J.V., Avruch, J., Woodgett, J.R., Kyriakis, J.M. and Force, T. (1994) The stress-activated protein kinases are major c-Jun amino-terminal kinases activated by ischemia and reperfusion. *J. Biol. Chem.* 269: 26546-26551.

Bird, T.A., Kyriakis, J.M., Tyshler, L., Gayle, M., Milne, A. and Virca, G.D. (1994) Interleukin-1 activates p54 mitogen-activated protein (MAP) kinase-stress-activated protein kinase by a pathway that is independent of p21ras, Raf-1 and MAP kinase kinase. *J. Biol. Chem.* 269: 31836-31844.

Sánchez, I., Hughes, R.T., Mayer, B.J., Yee, K., Woodgett, J.R., Avruch, J., Kyriakis, J.M. and Zon, L.I. (1994). Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. *Nature*. 372: 794-798.

Yan, M., Dai, T., Deak, J., Kyriakis, J.M., Zon, L.I., Woodgett, J.R., and Templeton, D.J. (1994) Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. *Nature*. 372: 798-800.

Pombo, C.M., Kehrl, J.H., Sánchez, I., Katz, P., Avruch, J., Zon, L.I., Woodgett, J.R. Force, T., and Kyriakis, J.M. (1995) Activation of the SAPK pathway by GC kinase, a human *STE20* homolog. *Nature*, Submitted.

Personnel:

The following personnel were paid from this grant during the period 8/19/94-8/28/95:

John M. Kyriakis, Ph.D. Principal Investigator
Irma Sánchez, Ph.D. Post Doctoral Research Fellow (from 7/1/95)
Árpád Molnár, M.D. Post Doctoral Research Fellow (from 4/1/95)
Anna Maria Forte, M.S. Research Technician

No graduate degrees were received during the period 8/19/94-8/28/95.

CONCLUSIONS: 8/94-8/95

With the conclusion that the SAPKs are part of a core signaling module which includes MEKK1 and SEK1, and that this module may be regulated *in situ* by GC kinase and other *STE20* homologues, it appears that the SAPK signaling pathway is strikingly

homologous to yeast signaling mechanisms (reviewed in 1). In yeast, multiple signal transduction mechanisms are regulated by modules consisting of members of the MEKK, MEK and ERK families of protein kinases arranged MEKK → MEK → ERK. These modules are, in turn regulated by an as yet uncharacterized mechanism, by members of the STE20 family of protein kinases (1). Accordingly, we plan to pursue the following studies for the forthcoming year:

1) *Continuation of the Yeast Two Hybrid Screen for SAPK Substrates.* Inasmuch as MAPKAP-K2 is not a SAPK substrate, we do not plan to pursue further MAPKAP-K2 experiments. Instead, we are continuing to characterize 103 clones isolated in a yeast two hybrid screen for SAPK-interacting polypeptides. We anticipate that many of these will be additional SAPK substrates.

2) *Identification of Additional MEKK Family Members which can Activate the SAPKs.* SAPKs may be part of multiple MEKK MEK ERK signaling modules. The mammalian MEKKs are a large family of protein kinases, of which at least six members exist. We are currently cloning additional MEKKs for use in expression studies to determine if these activate the SAPKs.

3) *Characterization of the Regulation and Substrates of GC Kinase.* We do not know the mechanism by which GC kinase activates the SAPK pathway. Accordingly, we are setting up a yeast two hybrid screen in order to identify polypeptides which interact with GC kinase. We anticipate that some of these will be GC kinase substrates and others will be species involved in GC kinase regulation.

4) *Identification of Additional STE20 Homologs which Can Activate the SAPK Pathway.* We are using a PCR-based approach to clone additional members of the mammalian Ste20 family which can activate the SAPK pathway. We have already isolated one such kinase PK-1, which is currently being tested as an activator of the SAPK pathway.

We are confident that these studies will be significant to the pathology of breast cancer. Specifically, the SAPKs are potently activated by TNF and IL-1. Inasmuch as c-Jun is a principal target of TNF action and is a SAPK substrate, the SAPKs play an important role in TNF and IL-1 action. Moreover, these cytokines have been shown to be potent inhibitors of breast cell growth. By understanding the SAPK pathway, and identifying all of the components in the SAPK signaling network, it will be possible to design more specific and effective inhibitors of breast cell neoplasias based on the SAPK pathway.

REFERENCES

- 1) Herskowitz, I. (1995) MAP kinase pathways in yeast: for mating and more. *Cell*. 80: 187-198.
- 2) Kyriakis, J.M., Banerjee, P., Nikolakaki, E., Dai, T., Rubnie, E.A., Ahmad, M., Avruch, J. & Woodgett, J.R. (1994) The stress-activated protein kinase subfamily of c-Jun kinases. *Nature*. 369: 156-160.
- 3) Sánchez, I, Hughes, R.T., Mayer, B., Yee, K., Woodgett, J.R., Avruch, J., Kyriakis, J.M. & Zon, L.I. (1994) Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun. *Nature*. 372: 794-798.
- 4) Lange-Carter, C.A., Pleiman, C.M., Gardner, A.M., Blumer, K.J. & Johnson, G.L. (1993) A divergence in the MAP kinase regulatory network defined by MEK kinase and Raf. *Science*. 260: 315-319.
- 5) Yan, M., Dai, T., Deak, J., Kyriakis, J.M., Zon, L.I., Woodgett, J.R. & Templeton, D.J. (1994) Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1. *Nature*. 372: 798-800.

- 6) Katz, P., Whalen, G. & Kehrl, J.H. (1994) Differential expression of a novel protein kinase in human B lymphocytes: preferential localization in the germinal center. *J. Biol. Chem.* 269: 16802-16809.
- 7) Rouse, J., Cohen, P., Trigon, S., Morange, M., Alonso-Llamazares, A., Zamanillo, D., Hunt, T. & Nebreda, A. (1994) A novel kinase cascade triggered by stress and heat shock that stimulates MAPKAP kinase-2 and phosphorylation of the small heat shock proteins. *Cell.* 78: 1027-1037.